Sangamo Therapeutics Sees Significant Pipeline Progress Amid Regulatory and Market Uncertainty
Sangamo Therapeutics, a company at the forefront of gene therapy and genomic medicine development, has made significant strides in its pipeline progress despite regulatory and market uncertainty. In its Q4 2025 conference call, the company's executives highlighted several key achievements that underscore its commitment to helping patients in need.
The company continued to demonstrate its leadership in the field of Fabry disease treatment with positive top-line results from the registrational STAR study. The study showed a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks across all dosed patients, which may serve as the primary basis for FDA approval under an accelerated approval pathway.
Moreover, Sangamo transitioned to become a clinical-stage neurology company with six clinical sites activated in the phase I/II STAND study in chronic neuropathic pain. This marks another significant milestone for the company, demonstrating its ability to adapt and expand its pipeline despite regulatory challenges.
In April 2025, Sangamo continued to demonstrate its position as a collaborator of choice for neurotropic capsids with the announcement of a third neurology capsid license agreement with Eli Lilly. This partnership will enable the delivery of genomic medicines for up to five central nervous system disease targets.
The company has also raised over $130 million in funding since the start of 2025 through non-dilutive license fees and milestone payments, as well as equity financing. These achievements are a testament to Sangamo's hard work and dedication to its mission.
Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo, provided an update on the company's prioritized pipeline during the conference call. She highlighted the progress made in the registrational phase I/II STAR study evaluating isaralgagene civaparvovec (ST-920) for the treatment of adults with Fabry disease.
The company has initiated a rolling submission of a BLA to the U.S. FDA seeking approval of ST-920 under an accelerated approval pathway. This approach allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis, rather than waiting for the entire BLA to be submitted at once.
The company has also submitted both the non-clinical and clinical modules to the FDA, as well as the antibody assay companion diagnostic designed to screen patients for eligibility with ST-920. The acceptance of this diagnostic by the FDA Center for Devices and Radiological Health (CDRH) seeking pre-market approval is another significant step forward for Sangamo.
Overall, the Q4 2025 conference call highlighted Sangamo's commitment to advancing its pipeline despite regulatory challenges and market uncertainty. With a strong track record of achievement and a clear focus on helping patients in need, the company remains well-positioned for continued growth and success."
